Ovarian PRP Injections for Infertility

Overseen By Jesse Hade, MD

Age: 18 - 65

Sex: Female

Trial Phase: Academic

Sponsor: Generation Next Fertility

Disqualifiers: Menopause, Perimenopause, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

180 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how injections of ovarian PRP, a treatment using a patient's own blood to potentially boost ovarian function, might improve embryo development in women undergoing IVF (in vitro fertilization). Participants will undergo two rounds of IVF—one before and one after the PRP treatment. The trial aims to determine if embryo quality improves, using time-lapse imaging and AI for analysis. Suitable participants should have a good ovarian reserve, meaning their ovaries can produce eggs, and be willing to undergo two IVF cycles. As an unphased trial, this study offers participants the chance to contribute to pioneering research that could enhance IVF success rates.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that ovarian PRP injections are safe for infertility treatment?

Research shows that ovarian PRP (platelet-rich plasma) injections are generally well-tolerated. Studies have found that these injections can positively affect the ovaries by improving hormone levels such as FSH (follicle-stimulating hormone) and AMH (anti-Müllerian hormone), which are important for fertility.

Although specific side effects from these injections are rarely reported, research has not identified major safety concerns, suggesting the treatment is relatively safe. However, like any medical procedure, there may be risks. Prospective participants should consult their healthcare provider before deciding to join a trial. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Ovarian PRP (Platelet-Rich Plasma) injections are unique because they aim to rejuvenate ovarian function and improve fertility differently than traditional treatments like hormone therapy or IVF alone. Researchers are excited about this approach because PRP uses growth factors from the patient's own blood to potentially enhance egg quality and ovarian response. Unlike conventional methods that primarily focus on stimulating the ovaries, PRP targets the underlying ovarian environment, offering a novel mechanism that could lead to better outcomes for individuals facing infertility.

What evidence suggests that ovarian PRP injections might be an effective treatment for infertility?

Research has shown that ovarian PRP (platelet-rich plasma) injections can enhance IVF treatment outcomes. One study found that these injections increased ovarian response and improved embryo quality. Another study linked PRP injections to retrieving more eggs from patients with a previous poor response to IVF. A review of multiple studies indicated that PRP injections can help the ovaries regenerate, leading to better pregnancy chances. In this trial, participants will undergo two IVF cycles: one before and one after receiving ovarian PRP injections, allowing for a direct comparison of embryo development and quality. These findings suggest that ovarian PRP injections may improve fertility treatments. ^{2 6 7 8 9}

Who Is on the Research Team?

Jesse Hade, MD

Principal Investigator

Generation Next Fertility

Are You a Good Fit for This Trial?

This trial is for women experiencing infertility issues, specifically those with poor embryo growth or low ovarian reserve. Participants should be candidates for in vitro fertilization (IVF). Details on who can't join are not provided.

Inclusion Criteria

My ovarian function is normal, as indicated by my AMH level.

I am willing to undergo two IVF cycles and oPRP treatment.

I have no health issues preventing IVF or PRP treatments.

Exclusion Criteria

Any health conditions that are contraindicated for IVF or oPRP treatment

Anovulation due to menopause or perimenopause

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

oPRP Treatment

Participants receive their first oPRP injection 1-2 weeks after the onset of the next menstrual cycle under IV sedation

1-2 weeks

1 visit (in-person)

Second IVF Cycle

Participants undergo a second IVF cycle with oPRP injection on stimulation days 2-5, followed by embryo development analysis using AI

4-6 weeks

Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including embryo quality and live birth rate

2 years

What Are the Treatments Tested in This Trial?

Interventions

• Ovarian PRP Injections

Trial Overview The study tests if injecting Platelet-rich plasma (PRP) into the ovaries can improve embryo quality during IVF. Embryo development will be monitored using advanced time-lapse imaging and AI analysis tools.

How Is the Trial Designed?

Group I: Embryo Development Before and After Ovarian PRP Using Time-Lapse AI Embryo Quality Score Experimental Treatment 1 Intervention

Patients will undergo two IVF cycles. The first cycle will be before ovarian PRP treatment and the second will be after. The embryo development measured by data gathered in time-lapse imaging and AI software will be used to determine differences between the groups within the same patient

Who Is Running the Clinical Trial?

Generation Next Fertility

Lead Sponsor

Trials

1

Recruited

230+

Citations

1. nature.com nature.com/articles/s41598-024-82630-1

Intraovarian platelet-rich plasma injection significantly ... This study evaluated the effectiveness of intraovarian platelet-rich plasma (PRP) injection in improving ovarian response and embryo quality in IVF patients.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9004561/

Ovarian reserve parameters and IVF outcomes in 510 ... After PRP injection, 22 women (4.3%) conceived spontaneously, 14 (2.7%) were lost to follow up, and 474 (92.9%) attempted IVF. Among women who ...

3. sciencedirect.com sciencedirect.com/science/article/pii/S2352320425001907

Research trends on platelet-rich plasma in improving ... The summary results of the Meta-Analysis indicated that injection of intraovarian PRP could promote ovarian regeneration and improve the reproductive outcomes ...

4. bmcpregnancychildbirth.biomedcentral.com bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-025-08178-8

Autologous platelet-rich plasma ovarian injection was ... Conclusion. Autologous PRP ovarian injection was associated with an increased number of oocytes retrieved in patients with poor response; ...

5. academic.oup.com academic.oup.com/humrep/advance-article/doi/10.1093/humrep/deaf030/8045480

Intraovarian platelet-rich plasma injection for ovarian ... Effect of intraovarian platelet-rich plasma injection on IVF outcomes in women with poor ovarian response: the PROVA randomized controlled trial ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10243509/

Intraovarian Platelet-Rich Plasma Injections The results of our observational study revealed that a PRP intraovarian injection is associated with improved ovarian tissue and function.

7. ovarianresearch.biomedcentral.com ovarianresearch.biomedcentral.com/articles/10.1186/s13048-024-01423-2

Platelet-rich plasma (PRP) treatment of the ovaries ... In several observational studies, ovarian PRP treatment improved Follicle stimulating hormone (FSH) and Anti-Müllerian hormone (AMH) levels, ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT05279560

Ovarian PRP (Platelet Rich Plasma) Injection for Follicular ... In the context of reproductive medicine, PRP has been proposed to increase pregnancy rates after uterine flushing in women with recurrent implantation failure ...

9. academic.oup.com academic.oup.com/humrep/article-abstract/39/4/760/7616814

Intraovarian platelet-rich plasma injection and IVF outcomes in ... The overall pregnancy rate per ITT was 43% (26 out of 60 patients). However, the percentage of clinical pregnancies was higher in the control ...